Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers have called for revised treatment guidelines to address the higher risk of fracture in the HIV population.
Ziagen is included in the combination-tablet regimens Triumeq and Trizivir and the two-drug combo tablet Epzicom.
The regimen of Tivicay (dolutegravir) and Epivir (lamivudine) would be a highly cost-effective first-line option and save a great deal.
Merck’s investigational hepatitis C treatment grazoprevir/elbasvir cured high rates of the virus among individuals coinfected with HIV.
Every decade spent living with HIV is equivalent to an additional 10 years of ordinary aging’s contribution to heart attack risk.
Various HIV antiretrovirals are linked to a raised risk of cardiovascular problems, although the overall risk of such an outcome is still low.
Multi-antiretroviral combination tablets appear to combat HIV no better than regimens that include individual tablets.
A revision of U.S. HIV treatment guidelines has removed Atripla (efavirenz/tenofovir/emtricitabine) from the priority list of first-line antir...
While antiretroviral therapy is beneficial for HIV-positive people with reduced kidney function, they should not take Viread (tenofovir).
There is an apparent link between taking Viread (tenofovir) and developing kidney damage among HIV-positive people with low body weight.
The FDA has approved Triumeq, ViiV Healthcare’s single-tablet, triple-combination antiretroviral regimen, as a first-line therapy to treat..
A majority of people taking antiretrovirals to treat HIV could switch to newer regimens with improved side effect profiles.
Early results of Merck’s combination hepatitis C therapy showed comparable safety between those with or without HIV, plus near-perfect cure ra...
ViiV Healthcare has submitted an application to the FDA for approval of a single-tablet regimen to treat HIV that combines Tivicay and Epzicom...
Treating HIV with a dual regimen of Kaletra and Epivir is as effective as a standard triple regimen of Kaletra plus two NRTIs.
The looming threat of a government shutdown on October 1 may spell potential delays in Food and Drug Administration approvals of new drugs.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.